Posted: Jul 12, 2021 02:32 GMT
Interim results of phase 3 trials carried out in Turkey with the Chinese CoronaVac vaccine against covid-19, showed an efficacy of 83.5% among the more than 10,000 volunteers between 18 and 59 years of age, reports the Daily Sabah newspaper, citing a study published in The Lancet.
The results show that the drug had a strong antibody response, while no serious side effects or deaths were reported among the volunteers. Side effects were minor, with the majority of adverse events of a mild nature and recorded within seven days after injection. The long-term efficacy of CoronaVac or against emerging variants such as Delta has not been studied.